Drugs play a key role in maintaining the health of farm animals and improving the economic condition of farm producers. The need for better productivity has become important more, as the population are looking for nutritious and disease-free food products. The pharmacologically active compounds help prevent the passing of diseases from animals to humans. Farm animal’s health have been considerably shaped by the use of drugs. Farm animal drugs are medicines used for healthcare-based practices for diagnosis, cure, mitigation, treatment, or prevention of diseases that could affect livestock. These medicines are used as per strict requirements based on their essentiality to maintain the well-being of farm animals. Simply said, farm animal drugs are a key factor supporting the growth of the livestock industry across the world.
Zoetis Inc. and MSD Animal Health– Notable Market Players in Farm Animal Drugs Market
The farm animal drugs market majorly consists of the players such as PHIBRO ANIMAL HEALTH CORPORATION, Zoetis Inc., Ceva, Elanco, Virbac, INTAS PHARMACEUTICALS LTD., Alembic Pharmaceuticals Limited, Boehringer Ingelheim International GmbH, MSD Animal Health, and Vetoquinol SA amongst others. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have adopted several inorganic and organic strategies to accelerate their growth and improve their market position.
Below is the list of the growth strategies done by the players operating in the farm animal drugs market:
| Company | Month & Year | Category | Description | ||
| Boehringer Ingelheim International GmbH | Sep-2021 | Collaboration | The company announced strategic collaboration with Invetx to develop novel, species-specific monoclonal antibody biotherapeutics targeting a wide range of diseases in the veterinary species. | ||
| MSD Animal Health | Aug-2021 | Partnership | The company announced the partnership with AAVMC on an international grant program created to help mitigate the global public health problem of antimicrobial resistance (AMR). Administered through the AAVMC’s Council on International Veterinary Medical Education (CIVME), the MSD Animal Health CIVME Antimicrobial Stewardship Grant program seeks to improve instructional programs related to AMR in educational institutions around the world. The program funds two grants for up to $10,000 over a maximum period of 24 months. | ||
| Ceva | Feb-2021 | Collaboration | Ceva announced that the company has signed a framework agreement with INRAE to work as a collaboration in animal health. The existing partnership in addition to licensing INRAE technologies, involves many forms of collaboration, including exchange of laboratory personnel, testing of anti-infective treatments and vaccines and several joint research projects – the European H2020 PIGS program – Program for Innovative Global Prevention of Streptococcus Suis – scheduled to be completed in 2021. | ||
| Elanco | Feb-2020 | Strategy and Business Planning | Elanco announced the signing of an agreement with Merck Animal Health to divest worldwide rights for Vecoxan. The deal was confirmed at an amount of US$55 million in cash | ||
| Elanco | Feb-2020 | Strategy and Business Planning | The company has signed an agreement to divest the European Economic Area and UK rights of Bayer AG’s the Drontal and Profender product families to Vetoquinol SA. | ||
|
Feb-2020 | Mergers and Acquisitions | The company announced the acquisition of Profender and Drontal product families from Elanco Animal Health. It will also acquire intellectual property, registrations and other rights currently owned by Bayer AG’s animal health business. | ||
| Elanco | Jan-2020 | Strategy and Business Planning | The company signed an agreement with PetIQ, Inc. to divest the US rights of Capstar, an oral tablet that kills fleas in dogs and cats to PetiQ. | ||
| Vetoquinol SA | Dec-2019 | Collaboration | The company has signed an agreement with Klox Technologies, the collaboration will target the innovations related to common companion animal’ skin conditions. | ||
| Ceva | Oct-2019 | Partnership | Ceva Santé Animale announce the signature of an exclusive license agreement with ProBioGen AG for the manufacture of vectorised poultry vaccines using ProBioGen’s proprietary AGE1.CR technology. | ||
| Ceva | Jul-2019 | Mergers and Acquisitions | Ceva announced that the company has successfully completed the acquisition of IDT Biologika GmbH veterinary biopharmaceutical and R&D activities. A new Global innovation center focused on swine vaccines was created within IDT’s exiting Dessau site. | ||
| MSD Animal Health | April-2019 | Mergers and Acquisitions | The company announced the acquisition of Antelliq Corporation. The acquisition has enabled to expand animal health by offering digital tracking, traceability and monitoring technology and complements the existing portfolio of vaccines and pharmaceuticals | ||
| Vetoquinol SA | April-2019 | Mergers and Acquisitions | The company announced the complete acquisition of Clarion Biociências developer, manufacturer, and distributor of veterinary medicine and non-medicinal products that target the livestock market. | ||
| Boehringer Ingelheim International GmbH | Oct-2021 | Expansion | The company announced an additional 100 million EUR investment in its veterinary public health capabilities in Lyon-Jonage, France, to aid governments and public health organizations in managing future emerging and transboundary diseases. | ||
| Zoetis Inc. | Jan-2020 | Expansion | Zoetis Inc. has further expanded its poultry vaccine portfolio with the introduction of Poulvac Procerta HVT-ND, a vectored recombinant vaccine that protects broiler chickens against Newcastle and Marek’s disease viruses. | ||
| Zoetis Inc. | June-2019 | Product Launch | Zoetis Inc. has reintroduced the vaccine Poulvac Coryza ABC IC3 to help U.S. poultry producers’ combat outbreaks of avian coryza, an acute respiratory infection, according to an announcement. |
